TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Overview

This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC. The relative bioavailability of tofacitinib released from TD-3504 compared to co-administered oral heavy-labeled tofacitinib (15N2-tofacitinib) will also be evaluated.

Full Title of Study: “Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD-3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: November 8, 2017

Interventions

  • Drug: TD-3504
    • TD-3504
  • Drug: 15N2-tofacitinib
    • 15N2-tofacitinib
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: TD-3504 Low-Dose
    • 6 healthy subjects and 6 ulcerative colitis subjects will be randomized to receive low-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
  • Experimental: TD-3504 Mid-Dose
    • 6 healthy subjects will be randomized to receive mid-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
  • Experimental: TD-3504 High-Dose
    • 6 healthy subjects will be randomized to receive high-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
  • Placebo Comparator: Placebo
    • 6 healthy subjects and 2 ulcerative colitis subjects to receive placebo orally single dose.

Clinical Trial Outcome Measures

Primary Measures

  • Safety & tolerability of TD-3504 by assessing the number, severity, and type of adverse events
    • Time Frame: Day 1 through Day 8
    • To assess the safety & tolerability of TD-3504 following single escalating doses of TD-3504 co-administered with a low dose of 15N2 tofacitinib for 8 days in healthy subjects and subjects with UC by assessing the number, severity, and type of treatment related adverse events.

Secondary Measures

  • Safety & tolerability of TD-3504 by assessing treatment related changes safety laboratory values
    • Time Frame: Day 1 through Day 8
    • To assess the safety & tolerability of TD-3504 following single escalating doses of TD-3504 co-administered with a low dose of 15N2 tofacitinib for 8 days in healthy subjects and subjects with UC by assessing treatment related changes safety laboratory values.
  • Systemic area under the curve of TD-3504
    • Time Frame: Day 1 through Day 4
    • To assess the systemic exposure of TD-3504 following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
  • Systemic Cmax of TD-3504
    • Time Frame: Day 1
    • To assess the systemic exposure of TD-3504 following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
  • Systemic area under the curve of tofacitinib
    • Time Frame: Day 1 through Day 4
    • To assess the systemic exposure of tofacitinib following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
  • Systemic Cmax of tofacitinib
    • Time Frame: Day 1
    • To assess the systemic exposure of tofacitinib following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
  • Systemic area under the curve of 15N2-tofacitinib
    • Time Frame: Day 1 through Day 4
    • To assess the systemic exposure of following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
  • Systemic Cmax of 15N2-tofacitinib
    • Time Frame: Day 1
    • To assess the systemic exposure of following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.
  • Tofacitinib relative bioavailability by area under the curve comparison
    • Time Frame: Day 1 through Day 4
    • To assess the relative bioavailability of tofacitinib from TD-3504 relative to 15N2-tofacitinib.
  • Tofacitinib relative bioavailability by Cmax comparison
    • Time Frame: Day 1
    • To assess the relative bioavailability of tofacitinib from TD-3504 relative to 15N2-tofacitinib.

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female between 18 to 55 years old – Male subjects must abstain from sexual intercourse or use a highly effective method of birth control – Women of child bearing potential must have a negative pregnancy test and either abstain from sex or use a highly effective method of birth control – Body Mass Index (BMI) 18 to 32 kg/m2 – Willing and able to give informed consent – Additional inclusion criteria apply Inclusion Criteria for Ulcerative Colitis (UC) subjects: – Subject has a history of UC – Subject is either not taking any medication for UC or has been taking a stable dose of ulcerative colitis medications for ≥ 14 days – Additional inclusion criteria apply Exclusion Criteria:

  • Is positive for hepatitis A, B or C, HIV or tuberculosis – Has clinically significant abnormalities in baseline laboratory evaluations – Subject has a clinically significant abnormal electrocardiogram (ECG) – Participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to screening (or within 60 days prior to screening if investigational drug was a biologic, or is currently participating in another trial of an investigational drug (or medical device) – Additional exclusion criteria apply Exclusion Criteria for Healthy Subjects: – Use of prescription drugs or any chronic over the counter medications within 14 days prior to clinic admission or requires continuing use during study participation, with the exception of hormonal contraceptives or hormone replacement therapy or standard daily multivitamin. – Additional exclusion criteria apply

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Theravance Biopharma
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Medical Monitor, Study Director, Theravance Biopharma

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.